Results
21
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
21 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ADOC | €6.23 | 18.7% | 39.8% | €93.7m | €6.30 | PS15.5x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
ALOKW | €19.10 | -1.2% | -26.8% | €157.8m | €30.30 | PE20.9x | E30.8% | n/a | Capital Goods | ||
VU | €139.10 | -1.2% | 4.9% | €2.2b | €195.20 | PE27.7x | E25.2% | 0.2% | Tech | ||
ALMUN | €0.48 | -0.4% | -83.8% | €4.3m | €1.30 | PB0.3x | E149.2% | n/a | Tech | ||
FDE | €29.20 | -0.5% | -25.5% | €152.7m | €60.33 | PE19.4x | E31.9% | n/a | Energy | ||
OSE | €6.57 | -5.9% | 90.7% | €142.9m | €10.15 | PS64.2x | E5.9% | n/a | Pharmaceuticals & Biotech | ||
ALICA | €10.70 | 5.9% | -25.7% | €86.5m | €16.00 | PE15.8x | E26.2% | 1.9% | Tech | ||
ALCUR | €6.78 | -0.6% | 172.3% | €39.1m | €8.48 | PE21.7x | E27.5% | n/a | Capital Goods | ||
MEDCL | €15.38 | 3.6% | 142.6% | €447.0m | €20.70 | PS37.4x | E69.6% | n/a | Pharmaceuticals & Biotech | ||
ALSMA | €4.27 | 12.1% | 72.2% | €22.3m | €5.80 | PE21x | E35.2% | n/a | Healthcare | ||
ALLIX | €8.00 | 0% | -27.8% | €52.0m | €13.50 | PS1.6x | E100.3% | n/a | Software | ||
S30 | €1.67 | -5.7% | -44.2% | €178.5m | €2.75 | PB1.6x | E101.6% | n/a | Software | ||
CLA | €1.79 | -5.6% | 7.1% | €101.5m | €4.75 | PE-20.3x | E90.6% | n/a | Software | ||
ALECP | €0.35 | -1.1% | -33.1% | €42.8m | n/a | PE47.6x | E86.8% | 0% | Media | ||
ALHOP | €23.00 | 9.0% | 29.9% | €66.1m | €30.05 | PE14.5x | E21.6% | 2.8% | Media | ||
ALCIS | €8.64 | 3.1% | -16.5% | €67.3m | €12.10 | PE21.1x | E56.5% | 1.9% | Commercial Services | ||
ATEME | €4.00 | 0.3% | -57.8% | €46.0m | €8.00 | PB1.2x | E96.4% | n/a | Tech | ||
OVH | €5.56 | -1.0% | -40.7% | €1.1b | €8.61 | PS1.1x | E101.1% | n/a | Software | ||
LSS | €28.25 | -0.9% | 7.0% | €1.1b | €34.75 | PE32x | E28.6% | 1.3% | Software | ||
ALPAT | €14.40 | 4.3% | 15.2% | €15.9m | €11.50 | n/a | E92.7% | n/a | Pharmaceuticals & Biotech | ||
EXN | €23.10 | -0.2% | 21.7% | €2.1b | €24.50 | PE48.5x | E28.4% | 0% | Software |